Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ATP2A2 | P16615 | 1/20 | 0.36 |
| ▸ | ATP2A3 | Q93084 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | TYR | P14679 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14189235 | 0.81 | CYP3A4 (0.47) | GABRA1GABRB2CA1ALDH1A1ALOX15 | |
| SCHEMBL19418006 | 0.80 | GABRA1 (0.37) | GABRA1GABRB2TAAR1CA1CA12 | |
| SCHEMBL1473762 | 0.78 | GABRA1 (0.36) | GABRA1GABRB2TAAR1CA1CA12 | |
| SCHEMBL12086412 | 0.78 | RIPK1 (0.36) | CA1CA12CA9ALDH1A1PTGS1 | |
| SCHEMBL10256479 | 0.78 | ALDH1A1 (0.40) | CA1ALDH1A1SMN1; SMN2TYRCYP2C9 | |
| SCHEMBL759007 | 0.76 | CA12 (0.41) | GABRA1GABRB2TAAR1CA1CA12 | |
| SCHEMBL10212115 | 0.76 | GABRA1 (0.42) | GABRA1GABRB2ALDH1A1ALOX15KDM4E | |
| SCHEMBL12343895 | 0.74 | ALDH1A1 (0.35) | ALDH1A1POLB | |
| SCHEMBL17464296 | 0.74 | TSHR (0.35) | HTTPOLB | |
| SCHEMBL12597843 | 0.74 | MAPT (0.34) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119409556-A | Preparation method of high-purity 2-bromo-4-tert-butyl-3, 5-difluorophenol | 大连奇凯医药科技有限公司 | 2025-02-11 | — | — | CN | claimed |
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | BAUSCH + LOMB IRELAND LIMITED (IE) | 2025-10-07 | — | — | US | disclosed |
| EP-4511114-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-119409556-A | Preparation method of high-purity 2-bromo-4-tert-butyl-3, 5-difluorophenol | 大连奇凯医药科技有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-119409556-A | Preparation method of high-purity 2-bromo-4-tert-butyl-3, 5-difluorophenol | 大连奇凯医药科技有限公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20240308965-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT | 2024-09-19 | — | — | US | disclosed |
| EP-3601388-B1 | BIS-BIPHENYL-PHENOXY CATALYSTS FOR OLEFIN POLYMERIZATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-08-07 | — | — | EP | disclosed |
| WO-2024109919-A1 | PYRIDONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 盛睿泽华医药科技（苏州）有限公司 | 2024-05-30 | — | — | WO | disclosed |
| EP-4313951-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| US-11851449-B2 | Heterocyclic amide compounds having an RORvt inhibitory action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-26 | — | — | US | disclosed |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | PFIZER INC | 2010-02-11 | — | — | US | disclosed |
| US-7622589-B2 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-7514457-B2 | Substituted aryloxymethyl bicyclicmethyl acetamide compounds | PFIZER INC. (US) | 2009-04-07 | — | — | US | disclosed |
| EP-1893583-A1 | SUBSTITUTED ARYLOXY-N-BICYCLOMETHYL ACETAMIDE COMPOUNDS AS VR1 ANTAGONISTS | Pfizer, Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| EP-1861359-A1 | N-(N-SULFONYLAMINOMETHYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | Pfizer, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097817-A9 | N- (N-SULFONYLAMINOMETHYL) CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | PFIZER JAPAN INC (JP) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006129164-A1 | SUBSTITUTED ARYLOXY-N-BICYCLOMETHYL ACETAMIDE COMPOUNDS AS VR1 ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2006-12-07 | — | — | WO | disclosed |
| US-20060270682-A1 | Substituted Aryloxymethyl Bicyclicmethyl Acetamide Compounds | PFIZER, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006097817-A1 | N- (N-SULFONYLAMINOMETHYL) CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN | PFIZER JAPAN INC. (JP) | 2006-09-21 | — | — | WO | disclosed |
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | PFIZER, INC. | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435040-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | TRPV1, TRPV3, TRPV2 | GABRA1 283/4885GABRB2 218/4885TAAR1 346/4885 |
| US-20060211741-A1 | Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists | CNR1, HVCN1, CNR2 | GABRA1 125/4885GABRB2 433/4885TAAR1 25/4885 |
| US-20240308965-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | TRPV1, TRPV3, TRPV2 | GABRA1 283/4885GABRB2 218/4885TAAR1 346/4885 |
| US-20100035880-A1 | SUBSTITUTED SULFONYLAMINOARYLMETHYL CYCLOPROPANECARBOXAMIDE AS VR1 RECEPTOR ANTAGONISTS | CNR1, HVCN1, CNR2 | GABRA1 121/4885GABRB2 390/4885TAAR1 24/4885 |
| US-11851449-B2 | Heterocyclic amide compounds having an RORvt inhibitory action | RORB, RORC, RORA | GABRA1 50/4885GABRB2 23/4885TAAR1 288/4885 |
| US-20060270682-A1 | Substituted Aryloxymethyl Bicyclicmethyl Acetamide Compounds | NR0B1, NR0B2, NR2C2 | GABRA1 238/4885GABRB2 284/4885TAAR1 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.